Literature DB >> 19024373

[The intensive care in the German Diagnosis Related Groups-System].

Cyril A Thix1, Alexander R Döbele, Klaus E Unertl.   

Abstract

The introduction of a prospective per case reimbursement system in the year 2004 in Germany put the high end intensive care medicine to a considerable financial risk on the basis of risk selection and high maintenance costs. To face this situation, the German Interdisciplinary Union for Intensive Care Medicine (DIVI) suggested to encode intensive care services as a DRG procedure and thus to make them relevant for reimbursement. That is the case now since 2007. The suggested procedure, called " complex intensive care treatment ", is based on a new intensive care scoring system ("Cost Predictor Score") which should quantify the costs per case. This paper provides an introduction into the GR-DRG (German Refined--Diagnosis Related Groups) health care reimbursement system and its financial implications for expensive hospital departments and presents a study carried out in the Anaesthesiological Intensive Care Unit of the Tübingen University Hospital examining the suitability of this new intensive care scoring system.

Mesh:

Year:  2008        PMID: 19024373

Source DB:  PubMed          Journal:  Bull Soc Sci Med Grand Duche Luxemb        ISSN: 0037-9247


  2 in total

1.  Effects of intensivist coverage in a post-anaesthesia care unit on surgical patients' case mix and characteristics of the intensive care unit.

Authors:  Marc Kastrup; Matthes Seeling; Stefan Barthel; Andy Bloch; Marie le Claire; Claudia Spies; Matthias Scheller; Jan Braun
Journal:  Crit Care       Date:  2012-07-18       Impact factor: 9.097

2.  How is intensive care reimbursed? A review of eight European countries.

Authors:  Martin-Immanuel Bittner; Maria Donnelly; Arthur Rh van Zanten; Jakob Steen Andersen; Bertrand Guidet; Jose Javier Trujillano Cabello; Shane Gardiner; Gerard Fitzpatrick; Bob Winter; Michael Joannidis; Axel Schmutz
Journal:  Ann Intensive Care       Date:  2013-11-12       Impact factor: 6.925

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.